22-Jun-2026 07:33:50
AUROPHARMAAcquisition and merger
AUROBINDO PHARMA USA ACQUIRES LANNETT COMPANY FOR $250 MN
• Aurobindo Pharma USA, Inc., a subsidiary of Aurobindo Pharma Limited, received FTC approval for the acquisition of Lannett Company LLC. • The transaction is valued at $250 million and is expected to close before the end of June 2026. • Lannett specializes in complex, non-opioid controlled substances, and its acquisition will expand Aurobindo USA's product offering and domestic manufacturing footprint with a site capacity of approximately 4 billion doses annually. • Impact: The transaction is expected to be immediately accretive to Aurobindo Group's earnings per share and generate cost efficiencies.
Aurobindo Pharma Limited
Open attachment